-
Cervical cancer is the second leading cause of cancer death among women worldwide, and more than 95% of cervical cancers contain human papillomavirus (HPV), particularly the high-risk HPV type 16 (HPV16)[9]. Though HPV screening can increase the likelihood of detecting premalignant lesions, it cannot eliminate HPV16 infection and still is difficult to adopt in developing countries. Additionally. there is still no effective countermeasures in clinical trials of cervical cancer in mid and late stage. Therefore the development of therapeutic vaccines targeted to HPV16 of vital importance in cervical cancer treatment.
Two HPV early oncoproteins, E6 and E7, are selectively retained and expressed in cervical tumors and are responsible for the malignant transformation[2, 5, 8]. These oncogenic proteins therefore represent ideal target antigens for developing vaccines and immunotherapeutic strategies against HPV-associated cervical cancer and its precancerous lesions. Recently, studies have clearly shown that a recombinant E6/E7 fusion protein is significantly more efficient in inducing antitumor protection than immunization with the E6 or E7 oncoprotein alone [12].
However, E6 and E7-based vaccines have some potential risks because of the oncogenic property of E6 and E7 and so appropriate genetic mutations to HPV16 E6 and E7 are indispensable to ensure the safety of the vaccine. It is reported that the mutants of L57G, C113R of the E6 gene and C24G, E26G of the E7 gene can not only eliminate their transformation capability but also retain the very good stability and antigenicity of E6 and E7 proteins[3, 6, 10].
In this research, a recombinant HPV16 E6E7 fusion gene with the codon-modification for the human gene was constructed, and site-directed mutagenesis at both L57G, C113R in the E6 protein and at C24G and E26G in the E7 protein were introduced into HPV16 E6E7 fusion protein [patent pending (CN 101100672)]. The optimized and recombinant HPV16 E6E7 mutant not only lost its transformation capability into NIH 3T3 cells and tumorigenicity in SCID mice, but also maintains good stability and antigenicity. Hopefully, the recombinant HPV16 E6E7 gene was constructed in this work can undergo further research as a potential therapeutic vaccines for HPV16-associated tumors.
HTML
-
Plasmid DNA construction
The HPV16 E6E7 fusion gene with the termination codon of E6 gene removed was optimized on the basis of the codon usage for mammalian cell expression.The optimized HPV16 E6E7 fusion gene (HPV16 ofE6E7) was then synthesized with the Splicing by Overlapping Extension PCR (SOE-PCR) (data not shown here). The HPV16 ofE6E7 gene with Kpn Ⅰ and Xba Ⅰ sites was cloned into the pUC18 vector that was cut using Kpn Ⅰ / Xba Ⅰ to generate pUC18/HPV16 ofE6E7.
For the generation of the pcDNA3.1(+)/ HPV16 omf E6E7 plasmid, a mutant of the HPV16 ofE6E7 gene at L57G, and C113R in the E6 protein and at C24G and E26G in the E7 protein with BamH Ⅰ/EcoR Ⅰ sites was amplified from pUC18/HPV16 ofE6E7 plasmid by SOE-PCR using the primers listed in Table 1.
Table 1. Primers used in this study
For generation of pcDNA3.1(+)/ HPV16 of E6E7 plasmid, HPV16 of E6E7 gene with BamH Ⅰ / EcoR Ⅰ sites was amplified from pUC18/ HPV16 ofE6E7 plasmid by PCR using primers E6Ubam and E7Leco (Table 1).
Both PCR products were then digested with BamH Ⅰ/ EcoR Ⅰ enzymes and cloned into the pcDNA3.1(+) vector that was cut by BamH Ⅰ / EcoR Ⅰ. All plasmid constructions were verified by DNA sequencing.
Cell culture and transfections
The NIH 3T3 cell line was purchased from American Type Culture Collection (Rockville, MD). TC-1 cells expressing HPV16 E6 and E7 were kindly provided by Dr. T.C. Wu of Johns Hopkins University. Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 1 mmol/L L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin. For stable transfection, pcDNA3.1 (+)/ HPV16 of E6E7 and pcDNA3.1(+)/ HPV16 omf E6E7 were transfected into NIH3T3 cells using a Lipofectamine 2000 liposome transfection kit (In-vitrogen, USA). The pcDNA3.1 empty vector transfection group and the blank control group (only liposome was added, and there was no vector DNA transfected) were established. Putative transfectants were then selected by antibiotic resistance in cell culture medium containing 800 μg/mL G418. After 3 weeks of culture in the presence of G418, the remaining cells were isolated with cloning cylinders and transferred into 24-well dishes.
Immunofluorescence imaging
To identify cell clones that carried the transfected HPV16 ofE6E7 and HPV16 omfE6E7 cDNAs, cells selected with G418 and growing in multi-tissue culture dishes (Corning, USA) were rinsed once with PBS, fixed for 30 min in iced 4% paraformaldehyde, washed in PBS, and permeabilized with 1% Triton X-100 in PBS. Cells were then treated with monoclonal antibody of mouse anti-HPV16 E7 (Santa Cruz, USA) for 1 h, washed 3 times in PBS, and incubated with Goat Anti-mouse IgG-FITC Antibody (Santa Cruz, USA). After extensive washing in PBS, the cells were viewed with a fluorescence microscope.
Western Blotting assay
NIH 3T3 cells (106) that had been transfected with pcDNA3.1(+)/ HPV16 ofE6E7, pcDNA3.1(+)/ HPV16 omfE6E7 and pcDNA3.1 empty vector were digested with buffer which contained 62.5 mmol/L Tris-HCl, pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol. The cell lysis samples were spun at 13 000 r/min for 5 min, the supernatants were then collected and loaded onto the 10% SDS-poly-acrylamide gel electrophoresis (SDS-PAGE). Protein on the gels was electro-transferred onto nitrocellulose membranes, and blocked with blocking buffer containing 5% of non-fat milk, the membrane was then incubated with primary antibodies against HPV16 E6 (polyclonal antibody of goat anti-HPV16 E6, Santa Cruz) at room temperature for two hours. After washing three times in PBS, 10 min each wash, the membrane was incubated with anti-goat Ig horseradish peroxidase linked secondary antibody (GE Healthcare Bio-Science, USA) at room temperature for one hour, and washed three times in PBS, 10 min each wash. The protein bands were then developed using an enhanced chemiluminescence (ECL) kit according to the manufacturer's specifi-cations (GE Healthcare Bio-Sciences), and visualized using the Gene-Genius Imaging System (Syngene, Frederick, MD, USA). The densities of the Western Blot bands were evaluated using the ImageJ Image Analysis Software.
Indentification of transforming activity
Colony formation assay
Colony formation assay was determined as described previously[1], with some modifications. Briefly, the NIH3T3 cell lines (1×103) expressing HPV16 ofE6E7 or HPV16 omfE6E7 were suspended in DMEM medium containing 10% FCS and 0.3% agarose and subsequently overlayed onto a solidified layer of DMED medium containing 10% FCS and 0.5% agarose. Cells were cultured for 21 days and cellular foci were photographed. The colonies were counted under a dissecting microscope. Five represen-tative images from each group were used to quantify foci area from three separate experiments. NIH 3T3 cells and vector-transfected NIH 3T3 cell lines were used as negative control, and the TC-1 cell line was used as the positive control.
Tumorigenesis assay and histologic analysis
NIH3T3 cell lines stably expressing HPV16 ofE6E7 or HPV16 omfE6E7 were used in a tumorigenesis assay. Cells were trypsinized, washed twice with PBS, resuspended at 5×107 cells per mL in PBS, and 0.1 mL of cell suspension was injected subcutaneously into NOD/SCID mice (8 mice in each group). All animals were monitored once a week for tumor formation. NIH 3T3 cells and vector-transfected NIH 3T3 cell lines were used as the negative controls, and the TC-1 cell line was used as the positive control.
The animals were sacrificed after xenograft tumor establishment, 5μm paraffin sections of xenograft tumors were stained with hematoxylin and eosin (H & E), three representative images from each section were obtained by light microscopic analysis after H & E staining.